Table_1_Efficacy of sotrovimab on omicron BA.2, BA.4 and BA.5 subvariants of sars-cov-2 vs. other early therapies: a systematic review and meta-analysis of literature data.docx

BackgroundThe aim of this meta-analysis was to ascertain whether sotrovimab was effective in reducing COVID-19 related hospitalization and mortality also in Omicron BA.2, BA.4 and BA.5 subvariants compared to other antivirals effective in index period.MethodsA systematic review and meta-analysis of Randomized Controlled Trials (RCTs) and observational studies comparing the efficacy of early treatment with sotrovimab compared to other early treatment effective in index period, antivirals or monoclonal antibodies (mAbs), in patients with COVID-19 during BA.2, BA.4, BA.5 waves, conducted in accordance with PRISMA guidelines. We searched MEDLINE, Google Scholar and the Cochrane Library. Mortality and hospitalization were defined as outcomes.ResultsFour studies were included, allowing a meta-analysis of 8,041 patients. Meta-analysis showed no statistical difference between groups in hospitalization and mortality. Precisely, the RR of mortality showed no difference in the sotrovimab group compared to treatment with other drugs (OR 0.38, 95% CI 0.10-1.49, pInterpretationIn conclusion, this meta-analysis showed no significant difference between sotrovimab or other antivirals in reducing COVID-19 evolution in patients with a high risk of progression, considering both hospitalization and mortality.</p

Peg-Interferon Plus Ribavirin with or without Boceprevir or Telaprevir for HCV Genotype 1: A Meta-Analysis on the Role of Response Predictors

<div><p>Background & aim</p><p>To compare the efficacy of pegylated-interferon (Peg-IFN) α-2a or α-2b and ribavirin given as dual therapy versus triple therapy (Peg-IFN and ribavirin plus boceprevir or telaprevir) in patients with HCV-1 chronic hepatitis naïve for anti-HCV therapy or relapsers to dual therapy in relation to the presence of constitutional, clinical and virological predictors of treatment response.</p><p>Methods</p><p>Included in the meta-analysis were studies meeting these criteria: original data from randomized trials on the efficacy of dual versus triple therapy in therapy-naïve patients or relapsers; at least one primary outcome clearly defined: sustained virological response in patients with or without rapid virological response (RVR), with genotype 1a or 1b, low or high HCV load, IL28-B CC or non-CC genotype, mild or severe fibrosis; odds ratio estimates of relative risk (RR) and 95% confidence intervals; English language; and published up to the end of June 2013.</p><p>Results</p><p>Seven original studies met the inclusion criteria, allowing a meta-analysis on 3,652 patients. Triple therapy was more effective than dual, regardless of IL-28B genotype, HCV sub-genotype, liver fibrosis, and baseline HCV load. In 1,045 patients who achieved RVR, SVR was more frequently achieved with dual therapy (RR = 1.11; <i>p</i> = 0.002) than triple. The same results were achieved when only the therapy-naïve patients were considered.</p><p>Conclusions</p><p>Triple therapy provides a significantly higher SVR rate than dual therapy, but dual therapy obtains a significantly higher SVR rate in patients with RVR. The data stress the clinical importance of a 4-week lead-in phase in direct-acting antiviral-based treatment.</p></div

Meta-analysis data on the achievement of SVR and tolerability with pegylated interferon α plus ribavirin or pegylated interferon α, ribavirin and a direct-acting antiviral in patients with chronic hepatitis C due to HCV genotype 1.

<p>SVR: sustained virological response; PR: pegylated interferon plus ribavirin; DAA: direct-acting antivirals; IL28-B: interleukin 28B; RVR: rapid virological response; AE: adverse events.</p

Forest plot showing the achievement of SVR in CHC patients without advanced liver fibrosis treated with pegylated interferon α-2 plus ribavirin or pegylated interferon α-2 plus ribavirin plus a direct-acting antiviral.

<p>Forest plot showing the achievement of SVR in CHC patients without advanced liver fibrosis treated with pegylated interferon α-2 plus ribavirin or pegylated interferon α-2 plus ribavirin plus a direct-acting antiviral.</p

Forest plot showing the achievement of SVR in CHC patients with low baseline HCV RNA treated with pegylated interferon α-2 plus ribavirin or pegylated interferon α-2 plus ribavirin plus a direct-acting antiviral.

<p>Forest plot showing the achievement of SVR in CHC patients with low baseline HCV RNA treated with pegylated interferon α-2 plus ribavirin or pegylated interferon α-2 plus ribavirin plus a direct-acting antiviral.</p

Forest plot showing the achievement of SVR in CHC patients with a rapid virological response treated with pegylated interferon α-2 plus ribavirin or pegylated interferon α-2 plus ribavirin plus a direct-acting antiviral.

<p>Forest plot showing the achievement of SVR in CHC patients with a rapid virological response treated with pegylated interferon α-2 plus ribavirin or pegylated interferon α-2 plus ribavirin plus a direct-acting antiviral.</p

Distribution of studies by quality scoring according to Jadad et al.

<p>Distribution of studies by quality scoring according to Jadad et al.</p

Forest plot showing the achievement of SVR in CHC patients with genotype 1b treated with pegylated interferon α-2 plus ribavirin or pegylated interferon α-2 plus ribavirin plus a direct-acting antiviral.

<p>Forest plot showing the achievement of SVR in CHC patients with genotype 1b treated with pegylated interferon α-2 plus ribavirin or pegylated interferon α-2 plus ribavirin plus a direct-acting antiviral.</p

Flow chart of the published studies evaluated for inclusion in the meta-analysis.

<p>Flow chart of the published studies evaluated for inclusion in the meta-analysis.</p

Forest plot showing the achievement of SVR in CHC patients with the IL28-B CC haplotype treated with pegylated interferon α-2 plus ribavirin or pegylated interferon α-2 plus ribavirin plus a direct-acting antiviral.

<p>Forest plot showing the achievement of SVR in CHC patients with the IL28-B CC haplotype treated with pegylated interferon α-2 plus ribavirin or pegylated interferon α-2 plus ribavirin plus a direct-acting antiviral.</p